Communications Equipment

ParkerVision, Inc.

ParkerVision, Inc. released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -0.0629

ParkerVision, Inc. released FY2025 Q3 earnings on November 12 (EST) with actual revenue of USD 0 and EPS of USD -0.0163

ParkerVision, Inc. released FY2025 Semi-Annual earnings on August 12 (EST) with actual revenue of USD 0 and EPS of USD -0.0463

ParkerVision, Inc. released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.0137

ParkerVision, Inc. released FY2025 Q1 earnings on May 13 (EST) with actual revenue of USD 0 and EPS of USD -0.0327

ParkerVision Reports Larger Net Loss in Q1 2025

ParkerVision, Inc. released FY2024 Q4 earnings on March 24, 2025 (EST), with actual revenue of 0 USD and EPS of -0.0312 USD

ParkerVision, Inc. released FY2024 annual earnings on March 24, 2025 (EST), with actual revenue of 0 USD and EPS of -0.16 USD.

ParkerVision, Inc. released FY2024 9 Months Earnings on November 13, 2024 (EST) with actual revenue of USD 0 and EPS of USD -0.1311

ParkerVision, Inc. released FY2024 Q3 earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -0.1196

ParkerVision, Inc. released FY2024 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -0.0078

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Ownership	%Owned	Share Chg	Report Date
Lewis H. Titterton	6.01%	5.56 M	18/11/2025
Gem Investment Advisors, LLC	4.4%	-5.46 M	04/08/2025
Thomas Frederick Staz	4.29%	10.19 K	04/08/2025
Paul A. Rosenbaum	1.4%	137.50 K	04/08/2025
Jeffrey L. Parker	0.36%	No Change	04/08/2025
Cynthia L. French	0.12%	No Change	04/08/2025
Robert G. Sterne	0.03%	No Change	04/08/2025
FNY Investment Advisers, LLC	0.01%	1.00 K	30/09/2025
Daniel M. Lewis	0%	-1.00	04/08/2025
Medivalor, A.V. Agencia de Valores, S.A.	0%	No Change	30/06/2025

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

ParkerVision, Inc. | 10-Q: FY2025 Q3 Revenue: USD 0

ParkerVision, Inc. | 10-Q: FY2025 Q2 Revenue: USD 0

ParkerVision, Inc. | 8-K: FY2025 Q2 Revenue: USD 0

ParkerVision, Inc. | 10-Q: FY2025 Q1 Revenue: USD 0

ParkerVision, Inc. | 8-K: FY2025 Q1 EPS: USD -0.03